Genomic and Personalized Medicine, Second Edition - winner of a 2013 Highly Commended BMA Medical Book Award for Medicine - is a major discussion of the structure, history, and applications of the field, as it emerges from the campus and lab into clinical action. As with the first edition, leading experts review the development of the new science, the current opportunities for genome-based analysis in healthcare, and the potential of genomic medicine in future healthcare. The inclusion of the latest information on diagnostic testing, population screening, disease susceptability, and pharmacogenomics makes this work an ideal companion for the many stakeholders of genomic and personalized medicine.
With advancing knowledge of the genome across and outside protein-coding regions of DNA, new comprehension of genomic variation and frequencies across populations, the elucidation of advanced strategic approaches to genomic study, and above all in the elaboration of next-generation sequencing, genomic medicine has begun to achieve the much-vaunted transformative health outcomes of the Human Genome Project, almost a decade after its official completion in April 2003.
- Highly Commended 2013 BMA Medical Book Award for Medicine
- More than 100 chapters, from leading researchers, review the many impacts of genomic discoveries in clinical action, including 63 chapters new to this edition
- Discusses state-of-the-art genome technologies, including population screening, novel diagnostics, and gene-based therapeutics
- Wide and inclusive discussion encompasses the formidable ethical, legal, regulatory and social challenges related to the evolving practice of genomic medicine
- Clearly and beautifully illustrated with 280 color figures, and many thousands of references for further reading and deeper analysis
Genomic and Personalized Medicine, Second Edition - winner of a 2013 Highly Commended BMA Medical Book Award for Medicine - is a major discussion of the structure, history, and applications of the field, as it emerges from the campus and lab into clinical action. As with the first edition, leading experts review the development of the new science, the current opportunities for genome-based analysis in healthcare, and the potential of genomic medicine in future healthcare. The inclusion of the latest information on diagnostic testing, population screening, disease susceptability, and pharmacogenomics makes this work an ideal companion for the many stakeholders of genomic and personalized medicine. With advancing knowledge of the genome across and outside protein-coding regions of DNA, new comprehension of genomic variation and frequencies across populations, the elucidation of advanced strategic approaches to genomic study, and above all in the elaboration of next-generation sequencing, genomic medicine has begun to achieve the much-vaunted transformative health outcomes of the Human Genome Project, almost a decade after its official completion in April 2003. Highly Commended 2013 BMA Medical Book Award for Medicine More than 100 chapters, from leading researchers, review the many impacts of genomic discoveries in clinical action, including 63 chapters new to this edition Discusses state-of-the-art genome technologies, including population screening, novel diagnostics, and gene-based therapeutics Wide and inclusive discussion encompasses the formidable ethical, legal, regulatory and social challenges related to the evolving practice of genomic medicine Clearly and beautifully illustrated with 280 color figures, and many thousands of references for further reading and deeper analysis
Abbreviations
| αDG | Alpha-dystroglycan |
| α-MSH | α-melanocyte stimulating hormone |
| β1-AR | β1-adrenergic receptor |
| μTAS | Micro total analysis system |
| 2D-PAGE | Two-dimensional polyacrylamide gel electrophoresis |
| 3C | Chromatin conformation capture |
| 5C | Chromosome conformation capture carbon copy |
| 6-MMP | 6-Methylmercaptopurine |
| 6MP | 6-Mercaptopurine |
| 6-MTIMP | 6-Methyl-thioinosine-monophosphate |
| 6-TGN | 6-Thioguanine nucleosides |
| 6-TIMP | 6-Thioinosinemonophosphate |
| 17q21 | Chromosome 17q21.31 duplication syndrome |
| a.a. | Amino acid |
| AAA | Abdominal aortic aneurysm |
| AABB | American Association of Blood Banks |
| AAH | Atypical adenomatous hyperplasia |
| ABC | Activated B cell |
| ABC | ATP-binding cassette |
| ABC DLBCL | Activated B-cell-like diffuse large B-cell lymphoma |
| ABCB1 | ATP-binding cassette, sub-family B, member 1 |
| ABI | Ankle brachial index |
| Abl | Abelson murine leukemia viral oncogene homolog |
| ABVD | Adriamycin, bleomycin, vinblastine, and dacarbazine |
| ACA | Anti-centromere antibodies |
| ACC | American College of Cardiology |
| ACCE | Analytical validity, clinical validity, clinical utility, and ethical, legal, and social implications |
| ACE | Angiotensin-converting enzyme |
| ACEi | Angiotensin-converting enzyme inhibitors |
| ACF | Aberrant crypt focus |
| aCGH | Array comparative genomic hybridization |
| ACL | Anterior cruciate ligament |
| ACO | Accountable care organization |
| ACR | Acute cellular rejection |
| ACR | American College of Rheumatology |
| ACS | Acute coronary syndrome |
| ACT | Artemisinin-based combination therapies |
| ACTH | Adrenocorticotropic hormone |
| ACTN1 | Alpha actinin |
| AD | Alzheimer disease |
| ADAM33 | ADAM metallopeptidase domain 33 |
| ADAR-1 | RNA-specific adenosine deaminase 1 |
| ADCC | Antibody-dependent cell-mediated cytotoxicity |
| ADEPT | Antibody-directed enzyme prodrug therapy |
| ADH | Alcohol dehydrogenase |
| ADH3 | Autosomal dominant hypercholesterolemia |
| ADHD | Attention deficit hyperactivity disorder |
| ADI-R | Revised autism diagnostic interview |
| ADME | Absorption, distribution, metabolism, and excretion |
| ADOS | Autism diagnostic observation schedule |
| ADP | Adenosine diphosphate |
| ADR | Adverse drug reaction |
| AE | Alternative expression |
| AED | Antiepileptic drugs |
| AF | Atrial fibrillation |
| AFAP | Attenuated FAP |
| AFib | Atrial fibrillation |
| AFLP | Amplified fragment length polymorphism |
| AFP | Alpha-fetoprotein |
| AGEN-BP | Asian Genetic Epidemiology Network blood pressure |
| Agr | Accessory gene regulator |
| AGT | Angiotensin I |
| AGTR1 | Angiotensin receptor 1 |
| AHA | American Heart Association |
| AHIC | American Health Information Community |
| AhpC | Alkyl hydroperoxide reductase |
| AHR | Aryl hydrocarbon receptor |
| AHRQ | Agency for Healthcare Research and Quality |
| AI | Allelic imbalance |
| AIDS | Acquired Immune Deficiency Syndrome |
| AIH | Autoimmune hepatitis |
| AIMs | Ancestry informative markers |
| Akt-v | Akt murine thymoma viral oncogene homolog |
| AKT | Protein kinase B (PKB) |
| AKI | Acute kidney injury |
| ALD | Alcoholic liver disease |
| ALK | Anaplastic lymphoma kinase |
| ALL | Acute lymphoblastic leukemia |
| ALM | Acral lentiginous melanoma |
| ALOX5 | 5’-Lipoxygenase |
| ALPS | Autoimmune lymphoproliferative syndrome |
| ALS | Amyotrophic lateral sclerosis |
| ALT | Alanine aminotransferase |
| AMA | American Medical Association |
| AMA1 | Apical membrane antigen 1 |
| AMCP | Academy of Managed Care Pharmacy |
| AML | Acute myeloid leukemia |
| AMP | Association of Molecular Pathologists |
| AMP | Adenosine monophosphate |
| AMPK | Adenosine monophosphate-activated protein kinase |
| AMR | Antibody-mediated rejection |
| AMT | Accurate mass tags |
| ANA | Antinuclear antibodies |
| ANG-1 | Angiopoietin 1 |
| ANG-2 | Angiopoietin 2 |
| ANKRD1 | Ankyrin repeat domain 1 |
| ANN | Artificial neural network |
| ANP | Atrial natriuretic peptide |
| APACHE II | Acute Physiology and Chronic Health Evaluation II score |
| APC | Drotrecogin-α (activated protein C) |
| APD | Action potential duration |
| ApiAP2 | Apicomplexan AP2 transcription factor |
| APOC3 | Apolipoprotein C3 (gene) |
| APOE | Apolipoprotein E (gene) |
| APP | Beta-amyloid precursor protein |
| AR | Adrenergic receptor |
| AR | Androgen receptor |
| ARB | Angiotensin receptor blocker |
| ARH | Autosomal recessive hypercholesterolemia |
| ARI | Acute respiratory infections |
| ARMD | Age-related macular degeneration |
| ARRA | American Recovery and Reinvestment Act |
| ARS | Axenfeld–Rieger’s syndrome |
| ARV | Antiretroviral |
| ARVC | Arrhythmogenic right ventricular cardiomyopathy |
| ASCO | American Society of Clinical Oncology |
| ASCVD | Atherosclerotic vascular disease |
| ASD | Atrial septal defect |
| ASD | Autism spectrum disorders |
| ASO | Antisense oligonucleotide |
| ASR | Analyte-specific reagent |
| AT | Angiotensin |
| ATG16L1 | Autophagy-related 16-like 1 |
| ATM | Ataxia telangectasia mutated |
| ATP | Adenosine... |
| Erscheint lt. Verlag | 30.10.2012 |
|---|---|
| Mitarbeit |
Chef-Herausgeber: Geoffrey S. Ginsburg, Huntington F Willard |
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
| Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik | |
| Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
| Technik | |
| ISBN-10 | 0-12-382228-9 / 0123822289 |
| ISBN-13 | 978-0-12-382228-4 / 9780123822284 |
| Haben Sie eine Frage zum Produkt? |
PDF (Adobe DRM)Größe: 87,8 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
EPUB (Adobe DRM)Größe: 58,5 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
